Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer

Completed · Phase 1

Conditions studied: Melanoma, Non Small Cell Lung Cancer

In brief

The purpose of this study is to evaluate the safety of enoblituzumab (MGA271) in combination with Yervoy (ipilimumab) when given to patients with B7-H3-expressing melanoma, squamous cell carcinoma of the head and neck (SCCHN), non small cell lung cancer (NSCLC) and other B7-H3 expressing cancers. The study will also evaluate what is the best dose of enoblituzumab to use when given with ipilimumab. Assessments will also be done to see how the drug acts in the body (pharmacokinetics (PK), pharmacodynamics) and to evaluate potential anti-tumor activity of enoblituzumab in combination with ipilimumab.

Key facts

Study ID

NCT02381314

Run by

MacroGenics

People needed

24

Starts

2015-03-26

Expected to finish

2018-09-26

Last updated by the study team

2022-02-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• UCLA Hematology-Oncology Clinic — Los Angeles, California, United States
• Yale University — New Haven, Connecticut, United States
• Mount Sinai Medical Center — Miami Beach, Florida, United States
• University of Chicago — Chicago, Illinois, United States
• Indiana University Simon Cancer Center — Indianapolis, Indiana, United States
• Washington University School of Medicine in St. Louis — St Louis, Missouri, United States
• Columbia University Medical Center — New York, New York, United States
• Providence Portland Medical Center — Portland, Oregon, United States
• Center for Oncology and Blood Disorders — Houston, Texas, United States
• University of Wisconsin — Madison, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.